The role of the microbiome in immune checkpoint inhibitor response and resistance
Dr Emiel De Jaeghere, medical oncologist at Ghent University hospital, selected three interesting highlights from the clinical science symposium on the role of the microbiome in immune checkpoint inhibitor response and resistance. He discussed the potential of a friendly-user score assessing gut dysbiosis to predict resistance to immune checkpoint inhibitors in routine practice. The association between intra-tumoral microbiome and clinical benefit from immunotherapy in patients with metastatic renal cell carcinoma was evaluated. He concluded with promising outcomes with fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.
With the educational support of:
